We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PFAS-Verbot könnte zu Engpässen bei Arzneimitteln führen.
- Abstract
The European Federation of Pharmaceutical Industries and Associations (EFPIA) warns of shortages of pharmaceuticals in Europe if the planned ban on per- and polyfluorinated alkyl substances (PFAS) is implemented without exceptions. The EFPIA argues that a blanket ban could jeopardize access to many medicines, even though the PFAS used in pharmaceuticals pose a low risk. The pharmaceutical sector uses a variety of materials that fall under the PFAS definition, and the restriction could impact the entire pharmaceutical manufacturing in the European economic area. The EFPIA has submitted a response to the consultation of the European Chemicals Agency to justify exemptions.
- Subjects
EUROPE; EUROPEAN integration; FLUOROALKYL compounds; PHARMACEUTICAL industry; TRADE associations; BLANKETS
- Publication
Pharma + Food, 2023, p25
- ISSN
1434-8942
- Publication type
Article